Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

While this condition can be caused by diabetes, tissue disease and neurological disorders, which damage the nerves and blood ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.